Equillium Inc.(EQ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EQ Equillium Inc.

Trading 04-23 09:43:56 EDT

0.4800

+0.0080

+1.69%

High0.4800	Low0.4800	Vol18.04K
Open0.4800	D1 Closing0.4720	Amplitude0.00%
Mkt Cap17.09M	Tradable Cap8.73M	Total Shares35.61M
T/O8.92K	T/O Rate0.10%	Tradable Shares18.18M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"EQ","market":"US","secType":"STK","nameCN":"Equillium Inc.","latestPrice":0.48,"timestamp":1745415435242,"preClose":0.472,"halted":0,"volume":18037,"delay":0,"floatShares":18182739,"shares":35609907,"eps":-0.228154,"marketStatus":"Trading","change":0.008,"latestTime":"04-23 09:43:56 EDT","open":0.48,"high":0.48,"low":0.48,"amount":8915.6891,"amplitude":0,"askPrice":0.5,"askSize":1128,"bidPrice":0.44,"bidSize":135,"shortable":3,"etf":0,"ttmEps":-0.228154,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745438400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1539316800000,"exchange":"NASDAQ","adjPreClose":0.472,"preHourTrading":{"tag":"盘前","latestPrice":0.48,"preClose":0.472,"latestTime":"05:28 EDT","volume":3000,"amount":1440,"timestamp":1745400499797},"postHourTrading":{"tag":"盘后","latestPrice":0.4799,"preClose":0.4799,"latestTime":"19:04 EDT","volume":9,"amount":4.0686,"timestamp":1745363086287},"volumeRatio":7.994197,"impliedVol":1.4019,"impliedVolPercentile":0.412},"requestUrl":"/m/hq/s/EQ/tweets","defaultTab":"tweets","newsList":[{"id":"2529396998","title":"EQ Resources Limited Appoints New Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2529396998","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529396998?lang=en_us&edition=full_marsco","pubTime":"2025-04-22 10:47","pubTimestamp":1745290041,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EQ Resources Limited ( ($AU:EQR) ). EQ Resources Limited has announced the appointment of Mr. Craig Richard Bra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eq-resources-limited-appoints-new-director?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eq-resources-limited-appoints-new-director?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4568","EQ"],"gpt_icon":0},{"id":"2529652773","title":"EQ Resources Strengthens Board with Industry Veteran Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2529652773","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529652773?lang=en_us&edition=full_marsco","pubTime":"2025-04-22 08:27","pubTimestamp":1745281634,"startTime":"0","endTime":"0","summary":"An update from EQ Resources Limited ( ($AU:EQR) ) is now available. EQ Resources Limited has appointed Craig Bradshaw, a veteran in the tungsten in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eq-resources-strengthens-board-with-industry-veteran-appointment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eq-resources-strengthens-board-with-industry-veteran-appointment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4568","EQ"],"gpt_icon":0},{"id":"2524214597","title":"Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2524214597","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524214597?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 21:55","pubTimestamp":1743515708,"startTime":"0","endTime":"0","summary":"Shares of Equillium, Inc.  have been struggling lately and have lost 52.2% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings of this company is a solid fundamental factor that enhances the prospects of a trend reversal for the stock.If this is not enough, you should note that EQ currently has a Zacks Rank #2 , which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market. You can se","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/equillium-eq-may-bottom-soon-135508577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EQ","BK4139","BK4568"],"gpt_icon":0},{"id":"2524900074","title":"EQ Resources Says Non-Executive Chairman to Become Executive Chairman on Interim Basis","url":"https://stock-news.laohu8.com/highlight/detail?id=2524900074","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524900074?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 08:56","pubTimestamp":1743468967,"startTime":"0","endTime":"0","summary":"EQ Resources  said that its current non-executive chairman, Oliver Kleinhempel, agreed to accept the role of executive chairman from Tuesday, according to a same-day Australian bourse filing.The appointment was made on an interim basis until a new chief executive officer is appointed, at which time the chairman's role will revert to a non-executive position.The appointment will assist with the transition of current CEO Kevin MacNeill to the role of chief technical officer, effective Tuesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4568","EQ","EQR.AU","BK4139","BK7095"],"gpt_icon":0},{"id":"2524907562","title":"EQ Resources Strengthens Leadership Team with Key Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2524907562","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524907562?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 08:19","pubTimestamp":1743466742,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EQ Resources Limited ( ($AU:EQR) ). EQ Resources Limited has announced key leadership changes to enhance its st...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eq-resources-strengthens-leadership-team-with-key-appointments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eq-resources-strengthens-leadership-team-with-key-appointments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4568","BK4120","EQ","TISI"],"gpt_icon":0},{"id":"2524977707","title":"Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive","url":"https://stock-news.laohu8.com/highlight/detail?id=2524977707","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524977707?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 21:23","pubTimestamp":1743427408,"startTime":"0","endTime":"0","summary":"Equillium, Inc. ( NASDAQ:EQ ) shareholders that were waiting for something to happen have been dealt a blow with a 47...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eq/equillium/news/revenues-working-against-equillium-incs-nasdaqeq-share-price","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EQ","NDAQ",".IXIC"],"gpt_icon":0},{"id":"2522578757","title":"Equillium Cut to Market Perform From Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2522578757","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522578757?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:52","pubTimestamp":1743162720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EQ/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 28, 2025 07:52 ET (11:52 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EQ"],"gpt_icon":0},{"id":"2522573178","title":"Equillium Full Year 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2522573178","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522573178?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:35","pubTimestamp":1743161752,"startTime":"0","endTime":"0","summary":"NasdaqCM:EQ Earnings and Revenue History March 28th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 12%. Earnings per share  also surpassed analyst estimates by 39%.Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are down 39% from a week ago.You should always think about risks. Case in point, we've spotted   4 warning signs for Equillium  you should be aware of, and 2 of them are a bit concerning.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/equillium-full-2024-earnings-beats-113552162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EQ"],"gpt_icon":0},{"id":"2522527498","title":"Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2522527498","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522527498?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:24","pubTimestamp":1743161050,"startTime":"0","endTime":"0","summary":"Equillium (EQ) has an average rating of overweight and mean price target of $3, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks an","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EQ"],"gpt_icon":0},{"id":"2522527340","title":"Equillium Inc : Leerink Partners Cuts to Market Perform From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2522527340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522527340?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:15","pubTimestamp":1743160539,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4139","EQ"],"gpt_icon":0},{"id":"2522529837","title":"Equillium downgraded to Market Perform from Outperform at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2522529837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522529837?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 18:16","pubTimestamp":1743157011,"startTime":"0","endTime":"0","summary":"Leerink analyst Thomas Smith downgraded Equillium (EQ) to Market Perform from Outperform with a price target of $1, down from $3. The company repor...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/equillium-downgraded-to-market-perform-from-outperform-at-leerink?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/equillium-downgraded-to-market-perform-from-outperform-at-leerink?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4139","EQ"],"gpt_icon":0},{"id":"2522652584","title":"Equillium Inc : Leerink Partners Cuts Target Price to $1 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2522652584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522652584?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 18:03","pubTimestamp":1743156209,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB071:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","EQ","BK4139"],"gpt_icon":0},{"id":"2522589511","title":"Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522589511","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522589511?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 00:12","pubTimestamp":1743091973,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/03/44519152/gold-gains-1-td-synnex-shares-plunge-after-downbeat-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUUD","BK4207","DRMA","SQQQ","BK4214","NQmain","BK4568","BK4139","USAW.SI","EQ","QLD","QID","USJW.SI","MNQmain","BK4161","TD","BK4149","BK4140","SLNO","BK4007","BK4023","TQQQ","SNX","BK4566","GTEC","BK4585","PSQ","TSYW.SI","BK4539",".IXIC","NXU","BK4561","NVIW.SI"],"gpt_icon":1},{"id":"2522339379","title":"Equillium reports EQUATOR study did not improve complete, overall response rates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522339379","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522339379?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:16","pubTimestamp":1743074208,"startTime":"0","endTime":"0","summary":"Equillium (EQ) announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of patients with acute graft-ver...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/equillium-reports-equator-study-did-not-improve-complete-overall-response-rates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/equillium-reports-equator-study-did-not-improve-complete-overall-response-rates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EQ","BK4568"],"gpt_icon":0},{"id":"2522768413","title":"BRIEF-Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2522768413","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522768413?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:13","pubTimestamp":1743073991,"startTime":"0","endTime":"0","summary":"BRIEF-Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host DiseaseMarch 27 (Reuters) - Equillium Inc EQ.O:EQUILLIUM ANNOUNCES RESULTS OF THE PHASE 3 EQUATOR STUDY OF ITOLIZUMAB ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUAJWXM1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","EQ"],"gpt_icon":0},{"id":"2522375002","title":"BRIEF-Equillium Reports Fourth Quarter and FY 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375002","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375002?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:11","pubTimestamp":1743073905,"startTime":"0","endTime":"0","summary":"BRIEF-Equillium Reports Fourth Quarter and FY 2024 Results March 27 (Reuters) - Equillium Inc EQ.O:EQUILLIUM Q4 REVENUE USD 4.392 MILLIONEQUILLIUM Q4 OPERATING INCOME USD -4.697 MILLIONEQUILLIUM Q4 BA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLXD01E37:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","EQ"],"gpt_icon":0},{"id":"2522837537","title":"Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522837537","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522837537?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA6TSVHQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4568","EQ"],"gpt_icon":0},{"id":"2522759993","title":"Equillium Inc - Breakthrough Therapy Designation Request Submitted to FDA, Feedback Expected During May 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522759993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522759993?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUAJWXM1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4139","EQ"],"gpt_icon":0},{"id":"2522755943","title":"Equillium Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients With Acute Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2522755943","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522755943?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUAJWXM1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EQ","BK4139","BK4568"],"gpt_icon":0},{"id":"2522375980","title":"Equillium Inc - Itolizumab Did Not Improve Response Rates at Day 29","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375980?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUAJWXM1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","EQ","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.equilliumbio.com","stockEarnings":[{"period":"1week","weight":0.0365},{"period":"1month","weight":-0.3792},{"period":"3month","weight":-0.2384},{"period":"6month","weight":-0.6066},{"period":"1year","weight":-0.7092},{"period":"ytd","weight":-0.3586}],"compareEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.0651},{"period":"3month","weight":-0.1306},{"period":"6month","weight":-0.0898},{"period":"1year","weight":0.0551},{"period":"ytd","weight":-0.1004}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.857143,"avgChangeRate":0.074209},{"month":2,"riseRate":0.571429,"avgChangeRate":0.328463},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.190483},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.11568},{"month":5,"riseRate":0.833333,"avgChangeRate":0.054615},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.145316},{"month":7,"riseRate":0.5,"avgChangeRate":0.343945},{"month":8,"riseRate":0.666667,"avgChangeRate":0.073981},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.069941},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.079943},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.050609},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.119129}],"exchange":"NASDAQ","name":"Equillium Inc.","nameEN":"Equillium Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Equillium Inc.(EQ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Equillium Inc.(EQ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Equillium Inc.,EQ,Equillium Inc.股票,Equillium Inc.股票老虎,Equillium Inc.股票老虎国际,Equillium Inc.行情,Equillium Inc.股票行情,Equillium Inc.股价,Equillium Inc.股市,Equillium Inc.股票价格,Equillium Inc.股票交易,Equillium Inc.股票购买,Equillium Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Equillium Inc.(EQ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Equillium Inc.(EQ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}